All GLG News Analyses Filed Under: Infectious Disease

Vaccinate Both Genders Against HPV

March 30, 2009

Analysis by: GLG Expert Contributor

Analysis of:A Vaccine Debate Once Focused on Sex Shifts as Boys Join the Target Market | www.washingtonpost.com

A Vaccine Debate Once Focused on Sex Shifts as Boys Join the Target Market | www.washingtonpost.com (view article) As  the vaccine protects the men it is obvious it protects their women partners and a chain of infection is borken.  This is axiomatic in contact infection control.  Surgeon General Parran demonstrated this a long time ago.

Not a unique product except perhaps in India

March 9, 2009

Analysis by: GLG Expert Contributor

Analysis of:Bharat Biotech launches Comvac5, single shot pentavalent combination vaccine | www.pharmabiz.com

-Combination vaccines are becoming the rule in the US and Europe.  In the U.S. we have the 5-in-1 combination vaccines Pentacel and Pediarix already in use. -In India a combination vaccine may come at too high a cost for widespread use

Peter BornsteinPartner and Consultant in Infectious DiseasesSt. Paul Infectious Disease Associates, Ltd

Trial set to fail?

March 5, 2009

Analysis of:Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) | www.pipelinereview.com

Novexel's trial of their novel beta-lactamase NXL104 combined with ceftazidime and metronidazole vs meropenem is an interesting choice.  While the Novexel arm looks to have very good activity against gram negative organisms and anaerobes, it almost completely lacks coverage against gram positive agents.  This appears to be a trial set to fail.

Treat African Violets not Bacillus anthracis

February 25, 2009

Analysis by: GLG Expert Contributor

Analysis of:Clue To Potential New Anthrax Treatment discovered in Houseplant Pest | www.medicalnewstoday.com

Renewed interest in iron binding via siderophores and blocking this component to prevent bacterial infections in man has opened up new revenues for research monies.  However, this approach was not productive nor efficient in past clinical trials and would not appear to be effective in treating respiratory anthrax. 

New Technology for treatment of sepsis

February 24, 2009

Analysis by: GLG Expert Contributor

Analysis of:Discontinuation of Development of TAK-242 for Severe Sepsis | www.pipelinereview.com

New technology has been developed that may play a role in the treatment of sepsis and hypoostension. This involves the development of a vagal nerve stimulator. A start-up company based in New Jersey- Electocore, has looked at animal models of epsis and hypotension and has found significant merit in their unique electrical signal for nerve stimulation to treat hypotension related to sepsis.

There is still hope for Takeda's antisepsis drug, TAK-242

February 24, 2009

Analysis by: GLG Expert Contributor

Analysis of:Discontinuation of Development of TAK-242 for Severe Sepsis | www.pipelinereview.com

TAK-242 is a novel, selective inhibitor of Toll-like receptor 4 (TLR4) signaling. TLR4 is the receptor for the "endotoxin" LPS, which is released from pathogens and causes sepsis and multiple organ failure. In contrast to many previous failed antisepsis drugs, TAK-242 appears to be a common pathway inhibitor, and as such has a better chance of success if the right patient population is treated.  The Phase III trial has been stopped after an interim analysis by the DSMB found not sufficient cytokine lowering by the drug.In my opinion, the patients, who would benefit most are the ones with "moderate"  or early stages of sepsis ( in advanced stages, no drug works!) and should be screened for ther specific microbial infection which would respond to the drug best.

Drug Act

February 23, 2009

Analysis by: GLG Expert Contributor

Analysis of:Irrational Use of Anti microbials | www.indmedica.com

Antibiotic , irrational use , drug act

Judicious use of antimicrobials

February 23, 2009

Analysis by: GLG Expert Contributor

Analysis of:Irrational Use of Anti microbials | www.indmedica.com

Good judgement and prudence on the part of the medical profession is the key to using antimicrobials to treat infectious diseases.  Education, correct diagnosis, proper use of laboratory medicine, bacterial isolation, antimicrobial susceptibility all need to accompany the use of antimicrobials. 

Inappropriate Antimicrobial Use is Not Only an American Problem

February 23, 2009

Analysis by: GLG Expert Contributor

Analysis of:Irrational Use of Anti microbials | www.indmedica.com

Useful life of antibiotics will decrease as broad spectrum resistance occurs. Multi-drug resistant pathogenic bacteria will be increasingly seen and cause increasingly severe disease

Potential for ondansetron is in supportive care to cancer patients (CINV and RINV) and post anesthesia (PONV)

February 19, 2009

Analysis by: GLG Expert Contributor

Analysis of:BioAlliance seeks European marketing nod for ondansetron RapidFilm | www.pharmabiz.com

Potential for ondansetron Rapid Film is based on increased convenience for the patients suffering from CINV and RINV There is also an opportunity with PONV

Previous Page : 12345678910Next51 to 60 of 362